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SUMMARY
Many studies have investigated the association between 
ergogenic substance use and symptoms of eating 
disorders, but not with the muscle dysmorphia risk 
level.  In this research, the practice of exercise, the use 
of anabolic steroids and nutrition supplements, among 
gym users at different risk levels for muscle dysmorphia, 
as well as the reasons for use were analyzed.  The 
association between the use of supplements and steroids 
and the drive for muscularity was also investigated. 
Participated 158 men gym users (age range: 16-
58 years), who completed three questionnaires: 
1) Substance use, 2) Drive for Muscularity Scale 
and 3) Muscle Appearance Satisfaction Scale.  The 
results indicated that 12.0 % of the gym users had 
a high risk of muscle dysmorphia, of these, 52.6 % 
use steroids and 89.5 % dietary supplements.  These 
substances are consumed mainly for cosmetic and 
physical appearance reasons.  The most commonly 
used steroids are testosterone, boldenone, stanozolol, 
trenbolone, and nandrolone decanoate.  The most 
popular supplements consumed are proteins, amino 
acids, glutamine, creatine and L-carnitine.  The use of 
steroids and supplements is associated positively and 
significantly with age, BMI, some characteristics of 
exercise, and attitudes and behaviors inherent in the 
drive for muscularity.  The importance of promoting 
measures that alert users to the consequences of the 
use and abuse of these substances, to contribute to 
risk-reduction of muscle dysmorphia is discussed.
Keywords: Androgenic anabolic steroids, dietary 
supplements, strength exercise, muscle dysmorphia.
RESUMEN
Muchos estudios han investigado la relación entre 
el consumo de sustancias ergogénicas y síntomas de 
trastornos alimentarios, pero no con el nivel de riesgo 
de dismorfia muscular.  En esta investigación, se analizó 
la práctica de ejercicio, el uso de esteroides anabólicos 
y de suplementos alimenticios, entre usuarios de 
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gimnasio con riesgo alto y riesgo bajo de dismorfia 
muscular, así como los motivos de uso.  También se 
investigó la relación entre el consumo de suplementos 
y esteroides con la búsqueda de la musculatura. 
Participaron 158 hombres (rango de edad: 16-58 
años), quienes completaron tres cuestionarios: 1) 
Uso de sustancias, 2) Escala de Motivación por 
la Musculatura y 3) Escala de Satisfacción con la 
Apariencia Muscular.  Los resultados indicaron que 
12.0 % de los participantes tenían riesgo alto de 
DM, de estos, 52.6 % consume esteroides y 89.5 % 
consumen suplementos alimenticios.  Estas sustancias 
son consumidas, principalmente, por razones estéticas 
y de apariencia física.  Los esteroides más consumidos 
son testosterona, boldenona, estanozolol, trembolona 
y decanonato de nandrolona.  Los suplementos de 
mayor consumo son proteína, aminoácidos, glutamina, 
creatina y L-carnitina.  El uso de esteroides y 
suplementos correlacionó positiva y significativamente 
con la edad, el IMC, con algunas características del 
ejercicio y con actitudes y conductas inherentes a la 
búsqueda de la musculatura.  Se discute la importancia 
de impulsar medidas que alerten a los usuarios sobre 
las consecuencias del uso y abuso de estas sustancias, 
para disminuir el riesgo de dismorfia muscular.
Palabras clave: Esteroides androgénicos anabolizantes, 
suplementos alimenticios, levantamiento de pesas, 
dismorfia muscular.  
INTRODUCTION
Muscle dysmorphia (MD) is a mental disorder 
characterized by over-concern about one’s size and 
body shape.  Despite looking at a hyper muscular 
body, people with MD perceive themselves as 
smaller and insufficiently muscular and they 
want to continue to gain muscle mass (1).  MD 
is more frequent in men (2,3), especially among 
those who do strength exercise, motivated to 
modify their physical appearance, the size and/or 
strength of the muscles (4).  In the latest version 
of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5), the MD is regarded as part of 
body dysmorphic disorder (5), nevertheless, many 
researchers have documented the similarities 
between MD and eating disorders (ED), and 
more specifically with anorexia nervosa (6-10). 
As well as in ED, also in MD, perceived social 
pressure is, directly and indirectly, related to 
driving for muscularity (DM), this is understood 
as the over-concern because one’s own body is 
insufficiently muscular.  DM is characterized by 
an emphasis on the diet (11) and on the practice 
of exercise to gain muscle mass (12); at the same 
time, DM predicts MD symptoms (13).
Similar to what happens in ED, people with 
MD have altered eating behavior (11).  This 
is characterized by the consumption of high 
amounts of protein and the intake of dietary 
supplements (DS), energizers, and illicit drugs 
such as anabolic-androgenic steroids (AAS), 
growth hormone, and thermogenic (14,15).  AAS 
are variants of testosterone and are produced 
synthetically.  AAS are used mainly by men, 
but not exclusively, since very early ages (16). 
Between 9.8 % and 29.3 % of those who practice 
strength exercise (17-25) have used AAS; and 
95 % have combined several of these substances 
by cycles (26), mainly to achieve the desired 
cosmetic effects.  AAS most commonly used 
by gym users are testosterone, testosterone 
decanoate, testosterone enanthate, nandrolone 
decanoate, boldenone undecylenate, boldenone, 
Dianabol, and growth hormone (18,20,21,25). 
On the other hand, DS is made with herbal 
products, plant extracts, dehydrated foods or fruit 
concentrates; and is used to increase the total 
dietary intake, to complement or supplement 
any component of it (27).  Between 49.4 % and 
84.7 % of gym users (28,29) consume at least 
four different DS (30).
The reasons given for the use of AAS and 
DS are, in the first place, cosmetic and physical 
appearance, to accelerate protein synthesis and 
improve athletic performance (19,20,23-24,31). 
Nevertheless, the use and consumption of DS are 
recommended by non-medical personnel (31,32): 
coaches, peers, gym personnel, and vendors. 
Common substances used include protein, amino 
acids, vitamins and minerals, meal replacements, 
L-carnitine, creatine, and sports/energy drinks. 
These substances are acquired, many times, from 
laboratories that have little control of them, and 
they can contaminate them with other substances 
such as AAS (33), which represents a risk to the 
health of consumers (31,34).
Due to medical (hepatic, cardiovascular, 
reproductive, endocrine, and dermatological) 
and psychiatric complications (increased 
aggressiveness, mood swings, and hostility), 
linked to the abuse of harmful substances used 
to build the muscles (31,34), researchers have 
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increased their interest in conducting studies 
related to the frequency of consumption, reasons 
for consumption, dose, and route of administration 
of DS and AAS, in different contexts: university 
students (24), gym users (17-18,20,23,35), 
bodybuilders (19,21,36) and other sports 
disciplines (25,37).  Also, it has long been 
known the relationship between AAS use and 
the cognitive and behavioral characteristics of 
ED (38).  Recently, this behavior has also shown 
an association with symptoms of MD (36). 
Likewise, consumption of DS has been linked 
to the desire to have a lean physical appearance 
and toned muscles (39).  At the same time, MD 
can influence both the initiation and maintenance 
of AAS use (40).
Although there are studies that have 
investigated substance use and its link to MD, 
these present some areas of opportunity in terms 
of 1) the measurement of the consumption of 
AAS and DS, because consumption has been 
measured from few questions; 2) the construct 
validity of the instruments used in men because 
previous studies have used ED instruments, which 
were designed to measure drive for thinness 
and not drive for muscularity, a situation that 
threatens the validity of the results, because 
body image concern in men differs qualitatively 
from women’s concern; 3) separate evaluation of 
substance use, since to our knowledge, studies 
have separately investigated the use of AAS and 
DS, in relation to MD; finally, 4) the AAS and DS 
consumed by people at high-risk and low-risk of 
MD have not been identified.  In this sense, this 
study aimed to investigate the characteristics of 
exercise practice; the type, quantity, and reasons 
for use, both of AAS and DS, according to the 
risk of MD, in a group of men who practice 
strength exercise in Mexican gyms, which have 
traditionally been considered high-risk places, for 
the involvement in the consumption of substances 
to improve sports performance and the aesthetic 
and body appearance.  Likewise, we investigate 
the association between the number of AAS and 
DS consumed with age, body mass index (BMI), 
the variables related to strength exercise, and the 
drive for muscularity.
Due to MD is linked to substance use (14,15) 
and exercise (12), we hypothesized that 
participants at high risk of DM would exercise 
more frequently, they would have a higher BMI, 
and report higher use of AAS and DS, than 
participants at low-risk of MD.
METHODS
Participants
The non-probabilistic intentional sample 
consisted of 158 men gym users, aged 16 to 58 
years old (M= 26.23, DE= 8.12), who practice 
strength exercise in ten gyms from Mexico 
State.  Most of the participants had high school 
(52.9 %) or university studies (31.6 %), the 
rest of the participants had primary (0.7 %), 
secondary (5.9 %), and postgraduate (2.6 %) 
studies.  Regarding marital status, most of 
the participants were single (83.8 %), 14.9 % 
were married or living together and 2.6 % were 
divorced.  Inclusion criteria: 1) attend the gym 
at least twice a week, for at least six months; 2) 
do physical exercise, at least two hours a week.
Instruments
Substance Use Questionnaire
Substance Use Questionnaire was developed 
from those proposed by Moura et al. (41) 
and Rodríguez et al. (29).  The questionnaire 
comprised 178 items divided into three sections: 
sociodemographic data (age, educational 
level, marital status, weight, and height); 
characteristics of the training (frequency, hours 
of training, reasons for exercising, participation 
in competitions); consumption and reasons for 
use of AAS and DS.  The last section included a 
list of 40 DS (e.  g.  protein, vitamins, minerals) 
and 63 AAS (e. g. testosterone, oxandrolone).
Drive for muscularity
DM was measured using two subscales of the 
Drive for Muscularity Scale (DMS; 42) and five 
subscales of the Muscle Appearance Satisfaction 
Scale (MASS; 43).  The DMS assesses the 
degree of concern of the people to increase their 
muscularity.  This scale consists of 15 Likert-type 
items, with possible responses varying between 
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1 (always) to 6 (never), higher scores indicate 
a greater drive for muscularity.  The DMS has 
demonstrated satisfactory internal consistency 
reliability and convergent validity with the desire 
for increased muscle mass (42).  In this study, 
we used two subscales: Attitudes to muscularity 
(w= 0.88) and Supplement consumption (w= 
0.75) from Mexican version (44).  The MASS 
measures the cognitive, behavioral, and affective 
domains of MD (43).  The Mexican version 
consists of 17 Likert-type items, with possible 
responses varying between 1 (strongly agree) 
to 5 (strongly disagree).  Three items (1, 4, and 
14) are inversely coded, with high scores reflect 
a tendency towards MD (45).  The MASS has 
demonstrated acceptable internal consistency 
reliability for full scale (w= 0.88) and its 
subscales: muscle checking (w= 0.77), which 
examines mirror checking and reassurance-
seeking behavior to evaluate muscle appearance; 
substance use (w= 0.81), assesses the willingness 
to use substances to gain muscle; bodybuilding 
dependence (w= 0.89), it evaluates excessive 
strength, exercise activity, and compulsive 
tendency to work out; muscle dissatisfaction (w= 
0.80), it refers to individual’s dissatisfaction with 
the own muscle size and shape; injury risk (w= 
0.86), it asses the symptoms of overtraining and 
beliefs related to unsafe, during strength exercise 
behavior.  To identify the level of risk of MD, we 
used the cut-off point (> to 58) proposed for the 
Spanish-speaking population by González-Martí 
et al. (36).  In this study, the internal consistency 
of the scale (w= 0.85) and its subscales (w= 0.67 
to 0.85) was adequate.
Procedure
First, the gym managers were contacted and 
their permission to carry out the investigation 
was requested.  Later, the gym users were 
contacted individually, they were informed about 
the aims of this study and they were invited to 
participate, guaranteeing the confidentiality 
of their data.  All participants gave informed 
consent and the protocol was approved by 
the Research Department of the Autonomous 
University of the State of Mexico.  In the case of 
two adolescents, who had not reached the age of 
consent, this was given by their parents and the 
adolescents gave informed assent.  Gym users 
answered the instruments individually, in gym 
facilities, during one or two sessions.  When the 
questionnaires were delivered, the researchers 
checked them to make sure that the instruments 
were fully answered.  Data were collected before 
the gyms closed their doors to the public, due to 
the SARS-CoV-2 pandemic, from August 2019 
to November 2019.  Participation was voluntary, 
and respondents did not receive any kind of 
compensation.
Data analysis
Data analysis was performed with the Statistical 
Package for the Social Sciences (SPSS, version 19 
for Windows).  Descriptive statistics were used for 
all variables.  Due to the nonparametric nature of 
the data, discrete variables were compared using 
the Mann–Whitney-U-test and Chi-square test. 
The Spearman correlation was used to evaluate the 
association between the number of AAS and DS 
consumed with age, BMI, the variables related to 
strength exercise, and the drive for muscularity.
RESULTS
Prevalence of high risk of MD
Based on the MASS cut-off point of the MASS 
(> to 58) proposed by González-Martí (36), gym 
users were classified into two groups (high-risk 
and low-risk of MD).  Of the 158 participants 
examined, 12.0 % (n = 19) were at high risk 
of developing MD.  Subsequent analyzes were 
performed based on this classification.
Sociodemographic and anthropometric 
characteristics, according to the risk of MD
Gym users in both groups (high-risk and 
low risk of MD) did not differ in their level 
of education (X2= 0.98, P= .96), marital status 
(X2= 0.95, P= .81), age (z= 0.23, P= .82) and 
BMI (z= 1.72, P= .09).  According to the World 
Health Organization classification (46), of 
the 19 participants in the high-risk group, 14 
(73.7 %) were overweight and five (26.3 %) 
were normal weight.  Contrary to it, more than 
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a third of the participants in the low-risk of MD 
group were normal weight (n= 51, 36.70 %), 
only one participant was underweight (0.72 %) 
and the rest were overweight (62.58 %).  No 
statistically significant differences were found 
in the proportion of BMI categories by the level 
risk of MD (X2 = 1.24(3), P= .74).  
Characteristics of the practice of exercise, 
according to the risk of MD
U Mann-Whitney test shows that the high-risk 
MD group obtained significantly higher scores 
in the training frequency (z= 2.14, P= .03) and 
the number of competitions (z= 2.45, P= .01), 
but not in the number of hours of training per 
week (z= 1.65, P= .10).  Likewise, most of the 
participants in both groups reported feeling 
uncomfortable when they missed their training 
(high-risk= 84.2 % and low-risk= 67.6 %).
AAS use, according to the risk of MD
More than half (52.6 %) of the participants at 
high risk of MD and almost a quarter (23.1 %) of 
those at low risk use AAS.  Statistically significant 
differences were found in the proportion of gym 
users who use AAS by the level risk of MD (X2= 
7.04(1), P= .008).  Participants at high-risk of MD 
use more AAS than those at low risk (z= 2.12, 
P= .007; Table 1).  The most commonly used 
steroids are testosterone, boldenone, stanozolol, 
trenbolone, and nandrolone decanoate.  For each 
one of the AAS, the percentage of gym users who 
consume them is higher in the group at high risk 
of MD (Table 2).  With respect to the reasons for 
consumption, 100 % of the participants in the 
high-risk group and 31.3 % of the low-risk group 
said that they use AAS to improve aesthetics and 
physical appearance.
DS use, according to the risk of MD
A high percentage of participants in both 
groups consumed DS (high-risk= 89.5 % and low 
risk= 66.4 %).  Statistically significant differences 
were found in the proportion of gym users who 
use DS by the level risk of MD (X2= 4.03(1), 
P= .045).  Participants at high-risk of MD use 
more DS than those at low risk (z= 2.81, P= 
.005; Table 1).  The most popular supplements 
consumed are proteins, amino acids, glutamine, 
creatine, and L-carnitine.  For each one of the 
DS, the percentage of gym users who consume 
them is higher in the group at high risk of MD 
(Table 2).  Most of the participants, both at high 
and low risk for MD, used DS for aesthetic and 
physical appearance reasons.
Association between the use of AAS and DS 
with age, BMI, strength exercise and drive for 
muscularity
As can be seen in Table 3, the use of AAS and 
DS was positively and significantly associated 
with age, BMI, hours of training per week, and 
participation in competitions.  The number of 
DS consumed also correlated with the training 
frequency.  Regarding the drive for muscularity, 
the number of AAS used correlated positively 
with the attitude towards the musculature, while 
the number of DS used correlated with the Injury 
risk and bodybuilding dependence (Table 3).
Table 1
Descriptive statistics of the number of AAS and DS used, according to the level risk of MD
Level risk of MD  AAS used   DS used
 Range M(SD) Md Range M(SD) Md
Hight (n = 19) 0-13 2.79 (4.04) 1 0-17 7.0 (4.64) 8
Low (n = 139) 0-10 0.99 (2.18) 0 0-21 4.11 (5.17) 2
Notes: MD= muscle dysmorphia; AAS= anabolic androgenic steroids; DS= dietary supplements; M= median; SD= standard 
deviation; Md= median.
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Table 2
Comparison in the use of AAS and DS, according to the level risk of MD
Type of substance Use   Level risk of MD            c2 P ES
   High         Low  (df = 1)  (phi)
 
   %   %   
AAS Testosterone            Yes 53.3   15.3  11.60 .001 0.32
  Not 46.7   84.7   
 Boldenone           Yes 40.0   11.2    8.43 .004 0.27
  Not 60.0   88.2   
 Stanozolol             Yes 33.3     8.2    8.10 .004 0.27
  Not 66.7   91.8   
 Trenbolone            Yes 26.7     9.2    3.91 .048 0.19
  Not 73.3   90.8   
 Nandrolone decanoate Yes 26.7     2.0  15.69 .001 0.37
  Not 73.3   98.0   
       
DS Proteins                  Yes 80.0   54.1   3.58 .05 0.18
  Not 20.0   45.9   
 Amino acids         Yes 66.7   32.7    6.45 .01 0.24
  Not 33.3   67.3   
 Glutamine               Yes 66.7   23.5  11.74 .001 0.32
  Not 33.3   76.5   
 Creatine                   Yes 66.7   27.6    9.04 .003 0.29
  Not 33.3   72.4   
 L-carnitine              Yes 60.0   26.5    6.82 .009 0.25
  Not 40.0   73.5   
Notes: MD= muscle dysmorphia; AAS= anabolic androgenic steroids; DS= dietary supplements; df= degrees of freedom; 
ES= effect size.
Table 3
Association between AAS and DS use with age, BMI, strength exercise, and drive for muscularity
  
  2 3 4 5 6 7 8 9 10 11 12 13 14
1. Age .34**** .36**** .01 .19* .35**** .26*** -.11 .19* -.16* -.22** .23** -.04 -.15
2. Body Mass 
 Index  .22** .16* .35**** .41**** .34**** .07 .22** .06 -.06 .35**** .17* .12
3. Training 
 frequency   .12 .07 .09 .17* .06 .07 .11  .02 .08 .23** .18*
4. Hours of 
 training per 
 week    .38**** .43**** .39**** .07 .35**** .02 -.12 .41**** .25*** .13
5. Participation 
 in competitions     .39**** .34**** .04 .23** -.03 -.04 .34**** .21** .08
6. Number of 
 AAS used      .46**** .19* .36**** .05 -.07 .40**** .13 .02
7. Number of DS 
 used       .14 .43*** .13 -.08 .54**** .28**** .27***
8. Attitudes to 
 muscularity         .55**** .45**** .47**** .50**** .36**** .40****
9. Ssupplement 
 consumption         .20** .17* .69**** .27*** .32****
10. Muscle 
 checking          .24** .36**** .34**** .50****
11. Muscle 
 dissatisfaction           .13 .13 .20*
12. Substance use            .40**** .36****
13. Injury risk             .47****
14. Bodybuilding 
 dependence             
Notes: AAS= anabolic androgenic steroids used; DS= dietary supplements used; *= P < .05; ** = P < .01; ***= P < .001; ****= P < .0001.
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DISCUSSION
This study aimed to investigate the 
characteristics of exercise practice; the type, 
quantity, and reasons for use, both of AAS and 
DS, according to the risk of MD, in a group of 
men who practice strength exercise in Mexican 
gyms.  First, we identified that 12 % (n = 19) 
of the participants were at high risk for DM. 
Results showed that participants at high risk of 
MD engage in strength exercise more frequently 
and have participated in more competitions, than 
participants at low risk of MD.  
The prevalence of AAS use was 52.6 % in 
users at high-risk of MD, this percentage was 
higher than that identified in previous studies 
with people who train with weight-lifting; in turn, 
the percentage of use in participants at low-risk 
(23.1 %) was similar to that reported in these 
studies (17-25).  Probably, this difference in 
consumption prevalence is because, in Mexico, 
no law regulates the prescription and sale of AAS, 
so those who consume them easily acquire them 
in the gym (sellers, instructors, and colleagues), 
online or pharmacies, even without a medical 
prescription.  These findings support the law 
initiative to reform Article 181 of General Health 
Law, proposed by the Veracruzana University, 
regarding the AAS prescription and use (47).
As in the international context (18,20,21,25), 
the most commonly used AAS are testosterone, 
boldenone, stanozolol, trenbolone, and nandrolone 
decanoate.  The reasons given by gym users at 
high-risk of MD were improving aesthetics/
physical appearance, which is consistent with 
other studies that have investigated the reason 
for consuming AAS in bodybuilders without 
MD symptoms (38).  Although AAS promote 
the development of physical capacities, it must 
be recognized that the use of these substances 
carries serious consequences, in the short, 
medium, and long term, putting at risk people’s 
health (34,48-50).
Regarding the prevalence of use DS, a high 
percentage of the participants in this study 
had consumed at least one DS (high-risk of 
MD = 89.5 %; low risk of MD = 66.4 %). 
This percentage is higher than that identified 
in Mexican gym users (32) and university 
students (51).  Probably, gyms are scenarios that 
enhance the DS use and the people are influenced 
or modeled by others.  At an international level, 
DS use among people who do strength exercise, 
the percentage of consumption ranges between 
54.5 % and 84.7 %.  The prevalence of DS use 
found in this study is slightly higher than that 
identified in other countries Chile, Spain, United 
States, and England (28-30,52).  Variability in the 
distribution of use DS may be due to variables 
such as the characteristics of exercise (e. g. 
time, type, hours spent) and of the participants 
(e. g. socioeconomic level, age, participation in 
competitions) and how collects the information (e. 
g. application of questionnaires during training, 
online surveys).
It should be noted that 50 % (n = 55) of users 
DS consume 5 or more of them.  Considering that 
many athletes unknown about adverse effects of 
DS use (53), it is important to implement strategies 
to monitor their consumption and warn people that 
the inappropriate use of these substances can have 
harmful effects on their health (e. g. liver toxicity, 
gastrointestinal disorders), especially when these 
are used in high doses (54).  In general, the most 
popular DS consumed are proteins, amino acids, 
glutamine, creatine, and L-carnitine.  Other 
studies have also identified proteins as the most 
frequently DS used in men (e. g., 30).
Similar to the results of research previous (30), 
in the present study, the main reasons given for 
DS use were to improve aesthetics and physical 
appearance, sports performance, and health; 
however, the National Institutes of Health (55) 
warns of the scant scientific evidence that supports 
the DS use to increase physical performance, 
development and muscle strengthening, etc. 
Furthermore, the existing literature about DS 
use has demonstrated several potential medical 
problems related to consumption.  The solution 
to this problem is to improve the information 
on the effects and consequences (positive and 
negative aspects) of its use.
Finally, AAS and DS use were associated with 
BMI and hours of training per week; in turn, the use 
of these substances was associated with the drive 
for muscularity, injury risk, and bodybuilding 
dependence.  Due to the consequences associated 
with substance use (48-50), as well as those 
associated with muscle dysmorphia (56), is 
important to promote strategies that contribute 
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to the psychological health of gym users.
Some strengths of the present research should 
be noted.  First, this research was focused on 
characterizing the exercise, the AAS and DS use 
in gym users, classified into high and low-risk of 
MD.  Second, we used measures designed and 
intended for use with men.  However, a limitation 
is the low number of people at high risk of MD, 
which limits the generality of the findings.  In 
this regard, it should be considered that the 
identification of gym users at high and low-risk 
of DM was derived from the cut-off point of the 
MASS proposed by González-Martí et al. (36); 
however, the Mexican version of this instrument 
consists of 17 items, while the proposed cut-off 
point was based on a 19-item version, so future 
studies should investigate the cut-off point for 
the Mexican MASS version.
CONCLUSION
Participants at high risk of DM do exercise 
more frequently and report higher use of AAS 
and DS, than participants at low risk of MD.  It 
is important to implement strategies to monitor 
their consumption and warn people that the 
inappropriate use of these substances can have 
harmful effects on their health.
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